IDEX vs Xylem
IEX and XYL side by side, both in general industrial machinery and equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IEX and XYL compare
Xylem is the larger company, worth 1.3 times as much as IDEX ($21.6B against $17.2B).
On earnings, Xylem is cheaper: it trades at 22.0× trailing earnings, against 33.6× for IDEX.
IDEX grew revenue faster over the last twelve months (7.3% versus 4.5% for Xylem).
IDEX keeps more of each dollar of sales as profit, with a net margin of 14.5% compared with 11.2% at Xylem.
Both pay dividends: IDEX yields 1.2% and Xylem 1.8%.
Xylem scores higher on the StockData Score (23 against 14 for IDEX), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IEX | XYL |
|---|---|---|
| Size and price | ||
| Market cap | $17.2B | $21.6B |
| Share price | $233.84 | $92.40 |
| Change, 1 year | 34.9% | −39.6% |
| Change, 5 years | −0.29% | −29.5% |
| Beta (5Y) | 0.83 | 0.99 |
| Employees | 8,700 | 22K |
| StockData Score | ||
| Total score | 14 | 23 (better) |
| Valuation score | 0 | 6 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 6 (better) |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 33.6× | 22.0× (better) |
| P/S | 4.8× | 2.4× (better) |
| P/B | 4.3× | 2.1× (better) |
| EV/EBITDA | 24.9× | 17.6× (better) |
| P/FCF | 26.9× | 22.5× (better) |
| PEG | – | 0.85 |
| FCF yield | 3.7% | 4.4% (better) |
| Fair value | $179.16 | $129.28 |
| Margin of safety | −30.5% | 28.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.3% (better) | 4.5% |
| Revenue growth, 5Y average | 8.0% | 13.1% (better) |
| Net income growth (TTM) | 10.7% (better) | 8.5% |
| EPS growth (TTM) | 12.4% (better) | 9.1% |
| EPS growth, 5Y average | 5.3% | 22.9% (better) |
| Profitability | ||
| Gross margin | 44.7% (better) | 39.2% |
| Operating margin | 20.7% (better) | 14.5% |
| Net margin | 14.5% (better) | 11.2% |
| FCF margin | 17.9% (better) | 10.5% |
| Return on equity | 13.0% (better) | 9.5% |
| Return on invested capital | 10.7% (better) | 8.7% |
| Financial health | ||
| Debt / equity | 0.46 | 0.28 (better) |
| Net debt / EBITDA | 1.67 | 1.25 (better) |
| Interest coverage | – | 57.4× |
| Current ratio | 3.05 (better) | 1.61 |
| Altman Z-score | 5.56 (better) | 3.15 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | 1.8% (better) |
| Payout ratio | 41.1% | 39.5% |
| Years of dividend growth | 5 | 13 (better) |
| Dividend growth, 5Y average | 7.3% | 9.0% (better) |
| Buyback yield | 1.7% | 5.8% (better) |
| Shareholder yield | 3.0% | 7.6% (better) |
| Ownership | ||
| Held by institutions | 102% | 93.2% |
| Held by insiders | 0.23% | 0.19% |
| Insider net buying, 12 months | −$3.3M | −$612K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.4% | 4.5% |
Go deeper
- IEX stock overview
- IEX income statement
- IEX valuation and score
- XYL stock overview
- XYL income statement
- XYL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.